CBD of Denver, Inc. CBDD announced its unaudited financial results on Friday for the second quarter, a three-month period ended June 30, 2024.
The Denver-based company reported $1,002,240 in revenue for the period, representing a 37.4% increase from $729,453 in the same period in 2023. That's slightly lower than previously expected. The company reported earlier this month that it would post $1.03 million in revenue for the second quarter.
In its recent business update, CBD of Denver shed light on its plans to get into the German market. Specifically, the company’s European subsidiary, Luxora received positive engagement in Berlin regarding a Near-Infrared (NIR) device used for cannabis testing. This happened on the heels of success at the recent Mary Jane Berlin trade fair, where it offered cannabis samples.
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
At the moment, it continues to navigate a complex regulatory environment in Germany as it seeks to establish and expand its operations.
![](https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/30111332/ccc-oct-24-banner__1_-30.gif)
That said, as of Aug. 21, 2024, nearly 300 applications for cannabis clubs in Germany have been submitted across various federal states, but only eight clubs have received approval, all in Lower Saxony. Germany legalized cannabis this past April.
Financial Highlights For Three Months Ended June 30, 2024
- Total operating expenses were $63,971, down from $182,333 in the second quarter of 2023, reflecting cost-saving measures.
- Salaries were reduced to $45,485, down from $131,526 in the prior year's quarter.
- Revenue was $2,125,562, a 109.4% increase from $1,015,232 in the same period in 2023, indicating strong sales momentum.
- Operating expenses decreased to $194,161 from $252,996 in the first six months of 2023, demonstrating improved operational efficiency.
- Salaries decreased to $137,171, compared to $174,237 in the same period last year.
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.